Adapting the COVID-19 Vaccine to New Sequence Variants

Time: 11:30 am
day: Day One


• mRNA is not only well suited for fast development of a vaccine for an emerging pandemic, but also in case of new virus variants
• This was put to a challenge with the emergence of the highly transmissive SARS-CoV-2 omicron variant
• The experience to switch as fast as possible and the biggest hurdles that have been encountered will be presented